CN111569039A - Traditional Chinese medicine preparation for treating communicating hydrocephalus and preparation method thereof - Google Patents
Traditional Chinese medicine preparation for treating communicating hydrocephalus and preparation method thereof Download PDFInfo
- Publication number
- CN111569039A CN111569039A CN202010585078.XA CN202010585078A CN111569039A CN 111569039 A CN111569039 A CN 111569039A CN 202010585078 A CN202010585078 A CN 202010585078A CN 111569039 A CN111569039 A CN 111569039A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- preparation
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 208000003906 hydrocephalus Diseases 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 201000003083 communicating hydrocephalus Diseases 0.000 title claims abstract description 36
- 241000208340 Araliaceae Species 0.000 claims abstract description 21
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 21
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 21
- 235000008434 ginseng Nutrition 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 16
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 16
- 244000197580 Poria cocos Species 0.000 claims description 14
- 235000008599 Poria cocos Nutrition 0.000 claims description 14
- 244000178320 Vaccaria pyramidata Species 0.000 claims description 14
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims description 14
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 14
- 235000008397 ginger Nutrition 0.000 claims description 14
- 241000132012 Atractylodes Species 0.000 claims description 11
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 11
- 240000008790 Musa x paradisiaca Species 0.000 claims description 11
- 235000015266 Plantago major Nutrition 0.000 claims description 11
- 241000208682 Liquidambar Species 0.000 claims description 10
- 235000006552 Liquidambar styraciflua Nutrition 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- JHGWQSGWUPCKNT-UHFFFAOYSA-N 2-tert-butyl-4-methyl-1,3,5-trinitrobenzene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O JHGWQSGWUPCKNT-UHFFFAOYSA-N 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 2
- 244000273928 Zingiber officinale Species 0.000 claims 4
- 210000000952 spleen Anatomy 0.000 abstract description 25
- 229940079593 drug Drugs 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 20
- 208000004880 Polyuria Diseases 0.000 abstract description 15
- 230000035619 diuresis Effects 0.000 abstract description 15
- 230000001939 inductive effect Effects 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 5
- 238000010792 warming Methods 0.000 abstract description 5
- 206010067482 No adverse event Diseases 0.000 abstract description 4
- 206010008118 cerebral infarction Diseases 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 238000011076 safety test Methods 0.000 abstract description 3
- 210000003128 head Anatomy 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 241000234314 Zingiber Species 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 8
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 201000011107 obstructive hydrocephalus Diseases 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 244000001632 Acorus gramineus Species 0.000 description 2
- 235000013073 Acorus gramineus Nutrition 0.000 description 2
- 244000036905 Benincasa cerifera Species 0.000 description 2
- 235000011274 Benincasa cerifera Nutrition 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000402754 Erythranthe moschata Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000012174 chinese wax Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000026500 emaciation Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 241001504424 Zosteropidae Species 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000007371 visceral function Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for treating communicating hydrocephalus and a preparation method thereof. The traditional Chinese medicine composition comprises, by weight, 610 parts of ginseng 585-. The medicines are used together to achieve the effects of invigorating spleen, warming yang, regulating qi, promoting diuresis, inducing resuscitation and dredging collaterals. Clinical tests prove that the effective rate of the traditional Chinese medicine composition for treating the patients with the cerebral infarction is up to 100%, and the traditional Chinese medicine composition has an obvious effect compared with the prior art which has an effective rate of 30%. And no adverse reaction is caused by safety test.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for treating communicating hydrocephalus and a preparation method thereof.
Background
The communicating hydrocephalus is caused by poor absorption or excessive secretion of cerebrospinal fluid and excretion disorder, has congenital pathological changes and acquired pathological changes, and the medicament in the prior art has poor treatment effect on the communicating hydrocephalus.
Disclosure of Invention
The invention provides a traditional Chinese medicine preparation for treating communicating hydrocephalus and a preparation method thereof, and solves the technical problem that the existing preparation has poor treatment effect on communicating hydrocephalus.
In order to achieve the purpose, one aspect of the embodiment of the invention provides a traditional Chinese medicine preparation for treating communicating hydrocephalus, which comprises the following raw materials, by weight, 610 parts of ginseng 585-.
Further, the traditional Chinese medicine preparation for treating communicating hydrocephalus comprises, by weight, 585 parts of ginseng, 450 parts of fried bighead atractylodes rhizome, 755 parts of poria cocos, 297 parts of dried ginger, 295 parts of cassia twig, 455 parts of exocarpium benincasae, 298 parts of cowherb seed, 292 parts of beautiful sweetgum fruit, 297 parts of plantain seed, 147 parts of acorus gramineus soland and 14 parts of artificial musk.
Furthermore, the traditional Chinese medicine preparation for treating communicating hydrocephalus comprises, by weight, 610 parts of ginseng, 460 parts of fried bighead atractylodes rhizome, 460 parts of poria cocos, 300 parts of dried ginger, 300 parts of cassia twig, 455 parts of exocarpium benincasae, 298 parts of cowherb seed, 292 parts of beautiful sweetgum fruit, 297 parts of plantain seed, 147 parts of grassleaf sweelflag rhizome and 14 parts of artificial musk.
Further, the traditional Chinese medicine preparation for treating communicating hydrocephalus is prepared from the following raw materials, by weight, 610 parts of ginseng, 470 parts of fried bighead atractylodes rhizome, 460 parts of poria cocos, 305 parts of dried ginger, 303 parts of cassia twig, 463 parts of exocarpium benincasae, 308 parts of cowherb seed, 303 parts of beautiful sweetgum fruit, 306 parts of plantain seed, 151 parts of grassleaf sweelflag rhizome and 16 parts of artificial musk.
Further, the traditional Chinese medicine preparation for treating communicating hydrocephalus is one of pills, granules or capsules.
In another aspect of the embodiment of the invention, a preparation method of traditional Chinese medicine granules for treating communicating hydrocephalus is provided, which comprises the following stepsDecocting ginseng, fried bighead atractylodes rhizome, poria cocos, dried ginger, cassia twig, exocarpium benincasae, cowherb seed, sweetgum fruit, plantain seed and rhizoma acori graminei in water twice, adding 10 times of water for the first time and 8 times of water for the second time, soaking for 30 minutes, and then decocting for 2 hours; (2) mixing the two decoctions, filtering, and concentrating under reduced pressure at-0.08 to-0.09 MPa and 60 to 70 ℃ until the relative density is 1.25 to 1.30 at 60 ℃ to obtain a clear paste; (3) adding sugar powder and dextrin, granulating, drying, adding artificial Moschus, mixing, packaging, and processing60COAnd (5) performing radiation sterilization to obtain a finished product.
Compared with the prior art, the ginseng tea has the beneficial effects that the ginseng tea takes the ginseng which can greatly tonify primordial qi and tonify spleen and lung as a monarch drug, and can promote the production of body fluid to quench thirst, calm the nerves and increase intelligence. The four medicines are used as ministerial medicines, wherein the white atractylodes rhizome, the tuckahoe, the dried ginger and the cassia twig have the effects of tonifying spleen and qi, eliminating dampness and inducing diuresis, and inducing diuresis and excreting dampness and invigorating spleen, so the Chinese medicinal composition has the effects of treating both principal and secondary aspects of people with weak spleen, slow transportation and water-dampness retention, the cassia twig can warm channels and activate yang and warm and transform water-dampness, the four medicines assist the main medicines to invigorate spleen and warm yang, dredge collaterals and induce diuresis, and the two medicines of the Chinese wax gourd peel and the plantain seed are respectively used for inducing diuresis to. Heart governs spirit and pathogenic factors are masked to clear orifices, so that spirit is blocked internally, while musk and grassleaf sweelflag rhizome both have pungent and fragrant flavor to move away and enter heart meridians, so as to open orifices and refresh mind. The cowherb seed is good at promoting blood circulation and vessels, can not walk but stay, has the effects of promoting blood circulation and dredging channels, and the sweetgum fruit is used for dredging channels and collaterals and is commonly used as an adjuvant drug. The active substance groups of the medicines are tightly cut to the body state after compatibility and combination so as to play a role. The medicines are used together to achieve the effects of invigorating spleen, warming yang, regulating qi, promoting diuresis, inducing resuscitation and dredging collaterals. Clinical tests prove that the effective rate of the traditional Chinese medicine composition for treating the patients with the cerebral infarction is up to 100%, and the traditional Chinese medicine composition has an obvious effect compared with the prior art which has an effective rate of 30%. And no adverse reaction is caused by safety test.
Drawings
FIG. 1 is a schematic representation of a skull CT before treatment of a typical patient according to an embodiment of the present invention.
Fig. 2 is a cranium CT after treatment of a typical patient according to an embodiment of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The terms "first" and "second," and the like, in the description and in the claims of embodiments of the present invention are used for distinguishing between different objects and not for describing a particular order of the objects. For example, the first parameter set and the second parameter set, etc. are used to distinguish different parameter sets, rather than to describe a particular order of parameter sets.
In the description of the embodiments of the present invention, the meaning of "a plurality" means two or more unless otherwise specified. For example, a plurality of elements refers to two elements or more.
The term "and/or" herein is an association relationship describing an associated object, and means that there may be three relationships, for example, a display panel and/or a backlight, which may mean: there are three cases of a display panel alone, a display panel and a backlight at the same time, and a backlight alone. The symbol "/" herein denotes a relationship in which the associated object is or, for example, input/output denotes input or output.
In the embodiments of the present invention, words such as "exemplary" or "for example" are used to mean serving as examples, illustrations or descriptions. Any embodiment or design described as "exemplary" or "e.g.," an embodiment of the present invention is not necessarily to be construed as preferred or advantageous over other embodiments or designs. Rather, use of the word "exemplary" or "such as" is intended to present concepts related in a concrete fashion.
According to the research, from the theory that spleen deficiency causes water flooding, blood stasis blocks brain orifices and water liquid stops accumulating in the brain, Guiling brain Tong granules with the functions of tonifying spleen and warming yang, regulating qi and promoting diuresis, and opening orifices and dredging collaterals are used for treating the brain diseases such as communicating hydrocephalus, severe obstructive hydrocephalus, encephaledema and the like, which belong to the symptoms of spleen deficiency and water flooding and brain orifices obstruction, so that the aim of improving the clinical curative effect is fulfilled.
Because communicating hydrocephalus is caused by poor absorption or excessive secretion of cerebrospinal fluid and excretion disorder, and has congenital pathological changes and acquired pathological changes, the traditional Chinese medicine considers that children are deficient in congenital and acquired disorder, true yang cannot warm spleen earth, spleen deficiency cannot promote diuresis, water dampness is not transformed, the hydrocephalus is accumulated in brain, brain orifices are obstructed, and water dampness phlegm invades brain due to deficiency, so that head suture is cracked, scalp is bright and swollen, and the sound of knocking is like kettle breaking. Spleen-kidney yang deficiency can lead to aversion to cold, cold limbs, weakness of spleen and stomach, and insufficiency of vital essence, so the face is white, eyes are not wonderful, white, dark and little, dull, spleen deficiency fails to have the function of health and transportation, so the limbs are emaciated, the appetite is poor, the stool is loose, and the urine is difficult. Therefore, it should improve the visceral function, and should be used to tonify spleen, warm yang, transform qi, induce diuresis, induce resuscitation and dredge collaterals on the premise of eliminating stagnant blood and hydrops, tonifying kidney, benefiting marrow and strengthening brain.
In the prescription, the first ginseng which can greatly tonify primordial qi and tonify spleen and lung is taken as a monarch drug, and the ginseng can promote the production of body fluid to quench thirst, calm the nerves and increase intelligence. The four medicines are used as ministerial medicines, wherein the white atractylodes rhizome, the tuckahoe, the dried ginger and the cassia twig have the effects of tonifying spleen and qi, eliminating dampness and inducing diuresis, and inducing diuresis and excreting dampness and invigorating spleen, so the Chinese medicinal composition has the effects of treating both principal and secondary aspects of people with weak spleen, slow transportation and water-dampness retention, the cassia twig can warm channels and activate yang and warm and transform water-dampness, the four medicines assist the main medicines to invigorate spleen and warm yang, dredge collaterals and induce diuresis, and the two medicines of the Chinese wax gourd peel and the plantain seed are respectively used for inducing diuresis to. Heart governs spirit and pathogenic factors are masked to clear orifices, so that spirit is blocked internally, while musk and grassleaf sweelflag rhizome both have pungent and fragrant flavor to move away and enter heart meridians, so as to open orifices and refresh mind. The cowherb seed is good at promoting blood circulation, can not walk but stay, has the effects of promoting blood circulation and dredging channels, and the sweetgum fruit is used for dredging channels and collaterals and is used as an adjuvant drug together. The medicines are used together to achieve the effects of invigorating spleen, warming yang, regulating qi, promoting diuresis, inducing resuscitation and dredging collaterals.
A traditional Chinese medicine preparation for treating communicating hydrocephalus comprises, by weight, 610 parts of ginseng 585-.
The medicines are used together to achieve the effects of invigorating spleen, warming yang, regulating qi, promoting diuresis, inducing resuscitation and dredging collaterals. Clinical tests prove that the effective rate of the traditional Chinese medicine composition for treating the patients with the cerebral infarction is up to 100%, and the traditional Chinese medicine composition has an obvious effect compared with the prior art which has an effective rate of 30%. And no adverse reaction is caused by safety test. Effectively solves the technical problem that the traditional Chinese medicine preparation in the prior art has poor treatment effect on the patients with the communicating hydrocephalus.
The clinical trials of the above formulation in my hospital are as follows:
all cases were from hospitalized children or outpatient children in our hospital, aged 6 months-56 years, with an average age of 2.9 years. Among 100 children patients, 70 male patients and 30 female patients. All cases have been diagnosed as communicating hydrocephalus and meet the spleen deficiency and water flood syndrome type standard.
Diagnostic criteria:
(1) head circumference exceeds the domestic standard by 2 standard deviations.
(2) Enlargement of fontanel, prolonged retention, tension, fullness or split skull.
(3) Sum-tenons may be in the shape of a sunset, or tremor, or strabismus.
(4) The intelligence is low.
(5) Speech retardation, or motor dysplasia, vomiting and convulsions, which are difficult to explain with other diseases.
(6) The imaging examination proves that the patient has obstructive hydrocephalus.
The disease can be diagnosed by the patients having one of the items (1) to (5) and (6).
The symptoms of traditional Chinese medicine
Type of spleen deficiency with water: excessive fontanel, obvious enlargement of the head, wide and split fontanel, cleft cranium, acute scalp light, skull percussion with a sound of a kettle-breaking sound, drop of eyes, white and dark, large and thin head and neck, head tilt, body weakness, late development, dull consciousness, language handicap, convulsion.
The main symptoms are: cracked head, white eyes without spirit, white face, bright scalp, thrashing with the head to make it look like a sound of thrashing, emaciation of limbs, inappetence, loose stool, dull expression and dysuria. The tongue is pale, with teeth marks on the tip and soft and smooth pulse.
The secondary symptoms are as follows: big head and thin neck, head tilt, emaciation, poor development, dull consciousness, bad speech and convulsion.
There are any two of the major symptoms and two of the minor symptoms.
The treatment method comprises the following steps:
test group, traditional Chinese medicine preparation for treating communicating hydrocephalus, specification: 5g per bag. 2 bags per day under 8 years old; the preparation is administered 3 bags each day for 3-4 times before meals over 8 years old.
Control group: the acezamide tablet (specification: 250mg per tablet, contrast drug produced by Beijing Yanjing pharmaceutical factory.) is administered with warm boiled water 5-10 mg/kg/day for 2 times/day. During the administration period, 2g of sodium bicarbonate, 1g of sodium citrate, 1g of potassium chloride, 1.5g of magnesium chloride and 1500-2000ml of drinking water can be used together daily to prevent the water electrolyte from being disturbed.
The above two groups of patients are treated every 4 weeks for 1 course. Continuously observing for 3 courses of treatment, wherein the follow-up is carried out once a week in an observation period, and patients with serious adverse reactions should be checked and recorded in time and treated according to symptoms. For those with adverse drug reactions, they should be treated with withdrawal.
The therapeutic effect judgment standard is as follows: the evaluation standard is formulated according to the evaluation standard of clinical efficacy for treating cephalocathartic (hydrocephalus) in the Chinese medical diagnosis and treatment standard and in combination with the evaluation standard of efficacy for obstructive hydrocephalus disease formulated in the national first TCM medical treatment Association.
And (3) healing: clinical symptoms disappear or basically disappear, and physical signs return to normal; the hydrocephalus is reduced by more than 75% by image examination.
The effect is shown: the clinical symptoms and physical signs are obviously improved; the reduction of hydrocephalus by 25-50% is detected by image.
The method has the following advantages: the clinical symptoms are improved, and the physical signs are improved; the reduction of hydrocephalus by 5-25% is detected by image.
And (4) invalidation: clinical symptoms and signs are unchanged or aggravated, and hydrocephalus is reduced by less than 5% in image examination.
The following table shows the results of the efficacy evaluations of the two groups of patients after 3 courses of treatment:
statistical tests show that p is less than 0.05, which indicates that the two groups of data have significant difference.
Safety evaluation criteria:
first-stage: safe and has no adverse reaction; the security index checks for no anomalies.
And (2) second stage: is safe, has mild adverse reaction, and can continue to treat without any treatment; the security index checks for no anomalies.
Third-stage: has safety problem, moderate adverse reaction or slight abnormality in safety index inspection, and can continue to be treated after treatment.
And (4) fourth stage: discontinuation of the test due to severe adverse reactions; or an abnormality is manifested upon checking the safety index.
The following table shows the safety accident results after 3 treatment courses for two groups of patients:
the two groups of data are statistically tested, and p is more than 1, which indicates that the two groups of data have no obvious difference. And the incidence rate of adverse reaction of the two groups of data is less than 95 percent by adopting chi-square test.
The treatment effect of the traditional Chinese medicine preparation for treating the communicating hydrocephalus is obviously better than that of a control group, and the Guiling brain-invigorating granules are fully proved to have good treatment effect and reliable safety.
Typical cases
Xie somebody, male, 6 months, Xian. Initial diagnosis time: the doctor visits the patient in 2017, 5 and 13 days. The infant is born in the same way in term, and the weight of the birth is 3300 g. The crying sound is weak in 1 week after the onset, and the patient cannot suck the tea, and repeated nodding and twitching appear after 1 month. The reaction is poor during the treatment, the neck is soft and the head can not be erected, the head circumference is 51cm, the bregma is 3 multiplied by 4.5cm, the fontanel is full, the scalp is bright, the eyes fall, the eyeball is horizontally tremor, the mouth is watery, the hand can not hold the object, the patient can not sit, and the limbs are not bent and stretched smoothly. The CT is found as follows: communicating hydrocephalus and brain hypoplasia. The CT image is shown in FIG. 1.
And (3) Western diagnosis: 1. communicating hydrocephalus.
2. Secondary epilepsy.
Traditional Chinese medicine diagnosis: relieving cranium (spleen deficiency and water flood type).
Treatment: the Chinese medicinal preparation for treating communicating hydrocephalus is taken orally with warm water 3 times before meal in 2 bags. After 3 treatment courses, the infant will raise its head, the number of twitch times is obviously reduced, bregma is 1.5X 1.5cm, the pattern of falling-day eyes is improved, nystagmus is not obvious, and the infant can actively hold the object with hands without running saliva. After two treatment courses, the infant patient can walk as a normal infant of the same age, the twitch symptom is completely disappeared, bregma is closed, the skull CT reexamination is normal, the result CT after treatment is shown in figure 2, and no abnormality exists at present in follow-up visits.
Example 1, the traditional Chinese medicine preparation for treating communicating hydrocephalus comprises, by weight, 585g of ginseng, 450g of fried rhizoma atractylodis macrocephalae, 755g of poria cocos, 297g of dried ginger, 295g of cassia twig, 455g of exocarpium benincasae, 298g of cowherb seed, 292g of fructus liquidambaris, 297g of semen plantaginis, 147g of rhizoma acori graminei and 14g of artificial musk.
Embodiment 2, the traditional Chinese medicine preparation for treating communicating hydrocephalus comprises, by weight, 610g of ginseng, 460g of fried bighead atractylodes rhizome, 460g of poria cocos, 300g of dried ginger, 300g of cassia twig, 455g of exocarpium benincasae, 298g of cowherb seed, 292g of beautiful sweetgum fruit, 297g of plantain seed, 147g of acorus gramineus soland and 14g of artificial musk.
Embodiment 3, the traditional Chinese medicine preparation for treating communicating hydrocephalus comprises, by weight, 610g of ginseng, 470g of fried rhizoma atractylodis macrocephalae, 460g of poria cocos, 305g of dried ginger, 303g of cassia twig, 463g of exocarpium benincasae, 308g of cowherb seed, 303g of fructus liquidambaris, 306g of semen plantaginis, 151g of rhizoma acori graminei and 16g of artificial musk.
Further, the traditional Chinese medicine preparation for treating communicating hydrocephalus is one of pills, granules or capsules.
In another aspect of the embodiment of the invention, a preparation method of traditional Chinese medicine granules for treating communicating hydrocephalus is provided, which comprises the following steps of (1) adding water into 610g of ginseng, 460g of fried rhizoma atractylodis macrocephalae, 460g of poria cocos, 300g of dried ginger, 300g of cassia twig, 455g of exocarpium benincasae, 298g of cowherb seed, 292g of fructus liquidambaris, 297g of semen plantaginis and 147g of rhizoma acori graminei and decocting for two times, adding 10 times of water for the first time and 8 times of water for the second timeSoaking in water for 30 min, and decocting for 2 hr; (2) mixing the two decoctions, filtering, and concentrating under reduced pressure at-0.08 to-0.09 MPa and 60 to 70 ℃ until the relative density is 1.25 to 1.30 at 60 ℃ to obtain a clear paste; (3) adding sugar powder 98g and dextrin 136g, granulating, drying, finishing, adding artificial Moschus 16g, mixing, packaging, and processing60COAnd (5) performing radiation sterilization to obtain a finished product.
The above embodiments are only used for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof; such modifications and substitutions do not depart from the spirit and scope of the present invention as set forth in the appended claims.
Claims (6)
1. A traditional Chinese medicine preparation for treating communicating hydrocephalus is characterized in that: the traditional Chinese medicine composition comprises, by weight, 610 parts of ginseng 585-.
2. The traditional Chinese medicine preparation for treating communicating hydrocephalus according to claim 1, which is characterized in that: the traditional Chinese medicine composition is prepared from the following raw materials, by weight, 585 parts of ginseng, 450 parts of fried bighead atractylodes rhizome, 755 parts of poria cocos, 297 parts of dried ginger, 295 parts of cassia twig, 455 parts of exocarpium benincasae, 298 parts of cowherb seed, 292 parts of fructus liquidambaris, 297 parts of plantain seed, 147 parts of rhizoma acori graminei and 14 parts of artificial musk.
3. The traditional Chinese medicine preparation for treating communicating hydrocephalus according to claim 1, which is characterized in that: the traditional Chinese medicine composition is prepared from the following raw materials, by weight, 610 parts of ginseng, 460 parts of fried bighead atractylodes rhizome, 460 parts of poria cocos, 300 parts of dried ginger, 300 parts of cassia twig, 455 parts of exocarpium benincasae, 298 parts of cowherb seed, 292 parts of beautiful sweetgum fruit, 297 parts of plantain seed, 147 parts of rhizoma acori graminei and 14 parts of artificial musk.
4. The traditional Chinese medicine preparation for treating communicating hydrocephalus according to claim 1, which is characterized in that: the traditional Chinese medicine composition is composed of the following raw materials, by weight, 610 parts of ginseng, 470 parts of fried bighead atractylodes rhizome, 460 parts of poria cocos, 305 parts of dried ginger, 303 parts of cassia twig, 463 parts of exocarpium benincasae, 308 parts of cowherb seed, 303 parts of sweetgum fruit, 306 parts of plantain seed, 151 parts of rhizoma acori graminei and 16 parts of artificial musk.
5. The traditional Chinese medicine preparation for treating communicating hydrocephalus according to any one of claims 1-4, which is characterized in that: the traditional Chinese medicine preparation for treating communicating hydrocephalus is one of pills, granules or capsules.
6. A preparation method of traditional Chinese medicine granules for treating communicating hydrocephalus is characterized by comprising the following steps: the preparation method comprises the following steps of (1) decocting ginseng, fried bighead atractylodes rhizome, poria cocos, dried ginger, cassia twig, exocarpium benincasae, cowherb seed, sweetgum fruit, plantain seed and grassleaf sweelflag rhizome in water twice, adding 10 times of water for the first time and 8 times of water for the second time, soaking for 30 minutes, and then decocting for 2 hours; (2) mixing the two decoctions, filtering, and concentrating under reduced pressure at-0.08 to-0.09 MPa and 60 to 70 ℃ until the relative density is 1.25 to 1.30 at 60 ℃ to obtain a clear paste; (3) adding sugar powder and dextrin, granulating, drying, adding artificial Moschus, mixing, packaging, and processing60COAnd (5) performing radiation sterilization to obtain a finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010585078.XA CN111569039A (en) | 2020-06-23 | 2020-06-23 | Traditional Chinese medicine preparation for treating communicating hydrocephalus and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010585078.XA CN111569039A (en) | 2020-06-23 | 2020-06-23 | Traditional Chinese medicine preparation for treating communicating hydrocephalus and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111569039A true CN111569039A (en) | 2020-08-25 |
Family
ID=72122055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010585078.XA Pending CN111569039A (en) | 2020-06-23 | 2020-06-23 | Traditional Chinese medicine preparation for treating communicating hydrocephalus and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111569039A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150290206A1 (en) * | 2012-12-03 | 2015-10-15 | Indiana University Research And Technology Corporation | Use of TRPV4 Antagonists to Ameliorate Hydrocephalus and Related Materials and Methods |
-
2020
- 2020-06-23 CN CN202010585078.XA patent/CN111569039A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150290206A1 (en) * | 2012-12-03 | 2015-10-15 | Indiana University Research And Technology Corporation | Use of TRPV4 Antagonists to Ameliorate Hydrocephalus and Related Materials and Methods |
Non-Patent Citations (1)
| Title |
|---|
| 李省让等: "《http://www.cntcm.com.cn/xueshu/2016-05/16/content_15110.htm》", 16 May 2016, 中国中医药报 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102283999B (en) | Traditional Chinese medicine preparation for treating insomnia | |
| CN102078487B (en) | Traditional Chinese medicine preparation for treating vertigo | |
| CN108524673A (en) | A kind of Chinese medicine composition and its application | |
| CN105232976B (en) | Composition for preventing or/and treating sub-health | |
| CN103341074A (en) | Application of Yixuanning granules in preparation of medicaments for treating insomnia | |
| CN111569039A (en) | Traditional Chinese medicine preparation for treating communicating hydrocephalus and preparation method thereof | |
| CN114869949B (en) | A pharmaceutical composition for treating puerperal diseases, and its preparation method | |
| CN104547928A (en) | Traditional Chinese medicine for treating pregnancy-induced syndromes | |
| CN104922488B (en) | A kind of Chinese medicine composition for preventing and treating Parkinson's or Parkinson's motor complication and its preparation method and application | |
| CN111714575A (en) | Traditional Chinese medicine preparation for treating severe hydrocephalus and preparation method thereof | |
| CN101199766B (en) | Medicament for treating epileps | |
| CN109464451B (en) | Medicine for treating neurasthenia and preparation method thereof | |
| CN107029037A (en) | It is a kind of to improve the eyesight-improving health care function patch of eyes based on nitric oxide principle | |
| CN105106734A (en) | Traditional Chinese medicine preparation for treating hyperemesis gravidarum | |
| CN118416149B (en) | Pharmaceutical composition for treating acute coronary syndrome kidney deficiency and blood stasis syndrome and application thereof | |
| CN100560117C (en) | A traditional Chinese medicine composition for invigorating spleen and stomach, nourishing liver and kidney and preparation method thereof | |
| CN105126008A (en) | Traditional Chinese medicine combination for treating infantile diarrhea and preparation method thereof | |
| CN103349709B (en) | Traditional Chinese medicine preparation capable of tonifying qi and yin and nourishing liver and kidney | |
| CN115120687B (en) | Traditional Chinese medicine composition for treating children enuresis and preparation method thereof | |
| CN111228367A (en) | Traditional Chinese medicine external lotion for treating infantile anaphylactoid purpura and preparation method thereof | |
| CN110151922B (en) | Traditional Chinese medicine composition for treating angina pectoris combined with hypertension and preparation method thereof | |
| CN120459224A (en) | Composition for improving children's sleep memory | |
| CN104996685A (en) | Health-care drink and preparation method thereof | |
| CN119280336A (en) | A Chinese medicine composition for treating Meige syndrome of heart and spleen deficiency type | |
| CN111617169A (en) | Traditional Chinese medicine ointment for treating hydrocephalus and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200825 |
|
| RJ01 | Rejection of invention patent application after publication |